136 related articles for article (PubMed ID: 26116017)
1. Differential behaviors of trastuzumab-sensitive and -resistant SKBR3 cells treated with menadione reveal the involvement of Notch1/Akt/FOXO1 signaling elements.
Sajadimajd S; Yazdanparast R
Mol Cell Biochem; 2015 Oct; 408(1-2):89-102. PubMed ID: 26116017
[TBL] [Abstract][Full Text] [Related]
2. Involvement of Numb-mediated HIF-1α inhibition in anti-proliferative effect of PNA-antimiR-182 in trastuzumab-sensitive and -resistant SKBR3 cells.
Sajadimajd S; Yazdanparast R; Akram S
Tumour Biol; 2016 Apr; 37(4):5413-26. PubMed ID: 26563369
[TBL] [Abstract][Full Text] [Related]
3. Sensitizing effect of juglone is mediated by down regulation of Notch1 signaling pathway in trastuzumab-resistant SKBR3 cells.
Sajadimajd S; Yazdanparast R
Apoptosis; 2017 Jan; 22(1):135-144. PubMed ID: 27770268
[TBL] [Abstract][Full Text] [Related]
4. Mycophenolic acid potentiates HER2-overexpressing SKBR3 breast cancer cell line to induce apoptosis: involvement of AKT/FOXO1 and JAK2/STAT3 pathways.
Aghazadeh S; Yazdanparast R
Apoptosis; 2016 Nov; 21(11):1302-1314. PubMed ID: 27651367
[TBL] [Abstract][Full Text] [Related]
5. Erythropoietin receptor expression and its relationship with trastuzumab response and resistance in HER2-positive breast cancer cells.
Zhang C; Duan X; Xu L; Ye J; Zhao J; Liu Y
Breast Cancer Res Treat; 2012 Dec; 136(3):739-48. PubMed ID: 23117856
[TBL] [Abstract][Full Text] [Related]
6. MiRNA‑542‑3p downregulation promotes trastuzumab resistance in breast cancer cells via AKT activation.
Ma T; Yang L; Zhang J
Oncol Rep; 2015 Mar; 33(3):1215-20. PubMed ID: 25586125
[TBL] [Abstract][Full Text] [Related]
7. Overcoming trastuzumab resistance in HER2-overexpressing breast cancer cells by using a novel celecoxib-derived phosphoinositide-dependent kinase-1 inhibitor.
Tseng PH; Wang YC; Weng SC; Weng JR; Chen CS; Brueggemeier RW; Shapiro CL; Chen CY; Dunn SE; Pollak M; Chen CS
Mol Pharmacol; 2006 Nov; 70(5):1534-41. PubMed ID: 16887935
[TBL] [Abstract][Full Text] [Related]
8. Pharmacological blockade of fatty acid synthase (FASN) reverses acquired autoresistance to trastuzumab (Herceptin by transcriptionally inhibiting 'HER2 super-expression' occurring in high-dose trastuzumab-conditioned SKBR3/Tzb100 breast cancer cells.
Vazquez-Martin A; Colomer R; Brunet J; Menendez JA
Int J Oncol; 2007 Oct; 31(4):769-76. PubMed ID: 17786307
[TBL] [Abstract][Full Text] [Related]
9. ErbB-2 inhibition activates Notch-1 and sensitizes breast cancer cells to a gamma-secretase inhibitor.
Osipo C; Patel P; Rizzo P; Clementz AG; Hao L; Golde TE; Miele L
Oncogene; 2008 Aug; 27(37):5019-32. PubMed ID: 18469855
[TBL] [Abstract][Full Text] [Related]
10. Activation of STAT3/HIF-1α/Hes-1 axis promotes trastuzumab resistance in HER2-overexpressing breast cancer cells via down-regulation of PTEN.
Aghazadeh S; Yazdanparast R
Biochim Biophys Acta Gen Subj; 2017 Aug; 1861(8):1970-1980. PubMed ID: 28499822
[TBL] [Abstract][Full Text] [Related]
11. Notch-1-PTEN-ERK1/2 signaling axis promotes HER2+ breast cancer cell proliferation and stem cell survival.
Baker A; Wyatt D; Bocchetta M; Li J; Filipovic A; Green A; Peiffer DS; Fuqua S; Miele L; Albain KS; Osipo C
Oncogene; 2018 Aug; 37(33):4489-4504. PubMed ID: 29743588
[TBL] [Abstract][Full Text] [Related]
12. A combination of trastuzumab and BAG-1 inhibition synergistically targets HER2 positive breast cancer cells.
Papadakis E; Robson N; Yeomans A; Bailey S; Laversin S; Beers S; Sayan AE; Ashton-Key M; Schwaiger S; Stuppner H; Troppmair J; Packham G; Cutress R
Oncotarget; 2016 Apr; 7(14):18851-64. PubMed ID: 26958811
[TBL] [Abstract][Full Text] [Related]
13. Amphiregulin confers trastuzumab resistance via AKT and ERK activation in HER2-positive breast cancer.
Kim JW; Kim DK; Min A; Lee KH; Nam HJ; Kim JH; Kim JS; Kim TY; Im SA; Park IA
J Cancer Res Clin Oncol; 2016 Jan; 142(1):157-65. PubMed ID: 26195282
[TBL] [Abstract][Full Text] [Related]
14. A new mechanism of trastuzumab resistance in gastric cancer: MACC1 promotes the Warburg effect via activation of the PI3K/AKT signaling pathway.
Liu J; Pan C; Guo L; Wu M; Guo J; Peng S; Wu Q; Zuo Q
J Hematol Oncol; 2016 Aug; 9(1):76. PubMed ID: 27581375
[TBL] [Abstract][Full Text] [Related]
15. CD147 knockdown improves the antitumor efficacy of trastuzumab in HER2-positive breast cancer cells.
Xiong L; Ding L; Ning H; Wu C; Fu K; Wang Y; Zhang Y; Liu Y; Zhou L
Oncotarget; 2016 Sep; 7(36):57737-57751. PubMed ID: 27363028
[TBL] [Abstract][Full Text] [Related]
16. EGFR over-expression and activation in high HER2, ER negative breast cancer cell line induces trastuzumab resistance.
Dua R; Zhang J; Nhonthachit P; Penuel E; Petropoulos C; Parry G
Breast Cancer Res Treat; 2010 Aug; 122(3):685-97. PubMed ID: 19859802
[TBL] [Abstract][Full Text] [Related]
17. Trastuzumab-resistant HER2-driven breast cancer cells are sensitive to epigallocatechin-3 gallate.
Eddy SF; Kane SE; Sonenshein GE
Cancer Res; 2007 Oct; 67(19):9018-23. PubMed ID: 17909003
[TBL] [Abstract][Full Text] [Related]
18. Yes1 signaling mediates the resistance to Trastuzumab/Lap atinib in breast cancer.
Takeda T; Yamamoto H; Kanzaki H; Suzawa K; Yoshioka T; Tomida S; Cui X; Murali R; Namba K; Sato H; Torigoe H; Watanabe M; Shien K; Soh J; Asano H; Tsukuda K; Kitamura Y; Miyoshi S; Sendo T; Toyooka S
PLoS One; 2017; 12(2):e0171356. PubMed ID: 28158234
[TBL] [Abstract][Full Text] [Related]
19. Inactivation of Rac1 reduces Trastuzumab resistance in PTEN deficient and insulin-like growth factor I receptor overexpressing human breast cancer SKBR3 cells.
Zhao Y; Wang Z; Jiang Y; Yang C
Cancer Lett; 2011 Dec; 313(1):54-63. PubMed ID: 21943825
[TBL] [Abstract][Full Text] [Related]
20. Olive oil's bitter principle reverses acquired autoresistance to trastuzumab (Herceptin) in HER2-overexpressing breast cancer cells.
Menendez JA; Vazquez-Martin A; Colomer R; Brunet J; Carrasco-Pancorbo A; Garcia-Villalba R; Fernandez-Gutierrez A; Segura-Carretero A
BMC Cancer; 2007 May; 7():80. PubMed ID: 17490486
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
